COMPARATIVE EFFECTIVENESS OF PROTON BEAM VERSUS PHOTODYNAMIC THERAPY TO SPARE THE VISION IN CIRCUMSCRIBED CHOROIDAL HEMANGIOMA.
Choroid
/ pathology
Choroid Neoplasms
/ diagnosis
Female
Fluorescein Angiography
/ methods
Follow-Up Studies
Hemangioma
/ diagnosis
Humans
Male
Middle Aged
Photochemotherapy
/ methods
Photosensitizing Agents
/ therapeutic use
Porphyrins
/ therapeutic use
Protons
Retrospective Studies
Tomography, Optical Coherence
Treatment Outcome
Verteporfin
/ therapeutic use
Visual Acuity
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 Feb 2021
01 Feb 2021
Historique:
pubmed:
15
5
2020
medline:
15
9
2021
entrez:
15
5
2020
Statut:
ppublish
Résumé
The aim of this study was to compare the functional and anatomical effectiveness of photodynamic therapy (PDT) versus proton beam therapy (PBT) in a real-life setting for the treatment of circumscribed choroidal hemangioma. A total of 191 patients with a diagnosis of circumscribed choroidal hemangioma and treated by PBT or PDT were included for analyses. The 119 patients (62.3%) treated by PDT were compared with the 72 patients treated by PBT. The final best-corrected visual acuity did not differ significantly between the two groups (P = 0.932) and final thickness was lower in the PBT compared with the PDT group (P = 0.001). None of the patients treated by PBT needed second-line therapy. In comparison, 53 patients (44.5%) initially treated by PDT required at least one other therapy and were associated with worse final best-corrected visual acuity (P = 0.037). In multivariate analysis, only an initial thickness greater than 3 mm remained significant (P = 0.01) to predict PDT failure with an estimated odds ratio of 2.72, 95% confidence interval (1.25-5.89). Photodynamic therapy and PBT provide similar anatomical and functional outcomes for circumscribed choroidal hemangioma ≤3 mm, although multiple sessions are sometimes required for PDT. For tumors >3 mm, PBT seems preferable because it can treat the tumor in only 1 session with better functional and anatomical outcomes.
Identifiants
pubmed: 32404844
pii: 00006982-202102000-00006
doi: 10.1097/IAE.0000000000002843
doi:
Substances chimiques
Photosensitizing Agents
0
Porphyrins
0
Protons
0
Verteporfin
0X9PA28K43
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-286Références
Shields CL, Honavar SG, Shields JA, et al. Circumscribed choroidal hemangioma: clinical manifestations and factors predictive of visual outcome in 200 consecutive cases. Ophthalmology 2001;108:2237–2248.
Madreperla SA, Hungerford JL, Plowman PN, et al. Choroidal hemangiomas: visual and anatomic results of treatment by photocoagulation or radiation therapy. Ophthalmology 1997;104:1773–1778.
Shields JA, Shields CL, Materin MA, et al. Changing concepts in management of circumscribed choroidal hemangioma: the 2003 J. Howard Stokes Lecture, Part 1. Ophthalmic Surg Lasers Imaging 2004;35:383–394.
Höcht S, Wachtlin J, Bechrakis NE, et al. Proton or photon irradiation for hemangiomas of the choroid? A retrospective comparison. Int J Radiat Oncol Biol Phys 2006;66:345–351.
Thariat J, Racadot S, Pointreau Y, et al. Intensity-modulated radiotherapy of head and neck cancers: dose effects on the ocular, orbital and eyelid structures [in French]. Cancer Radiother 2016;20:467–474.
Boixadera A, García-Arumí J, Arumí JG, et al. Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma. Ophthalmology 2009;116:100–105.e1–10.
Frau E, Rumen F, Noel G, et al. Low-dose proton beam therapy for circumscribed choroidal hemangiomas. Arch Ophthalmol 2004;122:1471–1475.
Mahdjoubi A, Dendale R, Desjardins L, et al. Treatment of exudative circumscribed choroidal hemangioma: efficacy of fractionated proton therapy (20 Gray relative biological effectiveness in 8 fractions). Retina 2019;39:692–699.
Schmidt-Erfurth UM, Michels S, Kusserow C, et al. Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results. Ophthalmology 2002;109:2284–2294.
Zeisberg A, Seibel I, Cordini D, et al. Long-term (4 years) results of choroidal hemangioma treated with proton beam irradiation. Graefes Arch Clin Exp Ophthalmol 2014;252:1165–1170.
Zografos L, Egger E, Bercher L, et al. Proton beam irradiation of choroidal hemangiomas. Am J Ophthalmol 1998;126:261–268.
Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006;47:371–376.
Levy-Gabriel C, Rouic LLL, Plancher C, et al. Long-term results of low-dose proton beam therapy for circumscribed choroidal hemangiomas. Retina 2009;29:170–175.
Jurklies B, Anastassiou G, Ortmans S, et al. Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol 2003;87:84–89.
Rosenbaum PR. Optimal matching for observational studies. J Am Stat Assoc 1989;84:1024–1032.
Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355–1360.
Ho YF, Chao A, Chen KJ, et al. Clinical outcomes and predictors of response to photodynamic therapy in symptomatic circumscribed choroidal hemangioma: a retrospective case series. PLoS One 2018;13:e0197088.
Papastefanou VP, Plowman PN, Reich E, et al. Analysis of long-term outcomes of radiotherapy and verteporfin photodynamic therapy for circumscribed choroidal hemangioma. Ophthalmol Retina 2018;2:842–857.
Shields CL, Dalvin LA, Lim LAS, et al. Circumscribed choroidal hemangioma: visual outcome in the pre-photodynamic therapy (PDT) vs PDT eras in 458 cases. Ophthalmol Retina 2020;4:100–110.
Cerman E, Çekiç O. Clinical use of photodynamic therapy in ocular tumors. Surv Ophthalmol 2015;60:557–574.
Blasi MA, Tiberti AC, Scupola A, et al. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes. Ophthalmology 2010;117:1630–1637.
Schlötzer-Schrehardt U, Viestenz A, Naumann GOH, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:748–757.
Arevalo JF, Shields CL, Shields JA, et al. Circumscribed choroidal hemangioma: characteristic features with indocyanine green videoangiography. Ophthalmology 2000;107:344–350.
Zografos L, Bercher L, Chamot L, et al. Cobalt-60 treatment of choroidal hemangiomas. Am J Ophthalmol 1996;121:190–199.
Naseripour M, Maleki A, Astaraki A, et al. RUTHENIUM-106 brachytherapy in the treatment of circumscribed choroidal hemangioma. Retina 2018;38:1024–1030.
Kivelä T, Tenhunen M, Joensuu T, et al. Stereotactic radiotherapy of symptomatic circumscribed choroidal hemangiomas. Ophthalmology 2003;110:1977–1982.
Tsina EK, Lane AM, Zacks DN, et al. Treatment of metastatic tumors of the choroid with proton beam irradiation. Ophthalmology 2005;112:337–343.
Thariat J, Grange JD, Mosci C, et al. Visual outcomes of parapapillary uveal melanomas following proton beam therapy. Int J Radiat Oncol Biol Phys 2016;95:328–335.
Schilling H, Sauerwein W, Lommatzsch A, et al. Long-term results after low dose ocular irradiation for choroidal haemangiomas. Br J Ophthalmol 1997;81:267–273.
Mayo C, Martel MK, Marks LB, et al. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 2010;76:S28–S35.